News

InBio and Beckman Coulter Partner to Advance Food Allergy Diagnostics

InBio, a global leader in high-quality, purified allergen proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, are collaborating to enhance the performance of basophil activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food Protein Standards and purified allergens with the Next-Generation Basophil Activation Test (BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These reagents are a critical component for BAT tests, and are validated for immunological consistency, ensuring reproducibility in high-sensitivity assays.

The Next-Generation BAT* by Beckman Coulter Life Sciences is a research use only breakthrough in functional allergy testing that offers researchers a powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging advanced flow cytometry and automation to measure basophil activation in response to allergen exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing variability and improving test interpretation.

The Next-Generation BAT powered by InBio allergens can test for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like